Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis
SCIE
SCOPUS
- Title
- Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis
- Authors
- Kim, SH; Kim, SH; Bahn, JW; Kim, YK; Chang, YS; Shin, ES; Kim, YS; Park, JS; Kim, BH; Jang, IJ; Song, J; Kim, SH; Park, HS; Min, KU; Jee, YK
- Date Issued
- 2009-11
- Publisher
- FUTURE MEDICINE LTD
- Abstract
- Aims: Although some genetic risk factors have been reported for the development of hepatitis due to anti-TB drugs, an extensive candidate gene approach evaluating drug-metabolizing enzymes has not been attempted. This study aimed to investigate the association of genetic polymorphisms in drug-metabolizing enzymes with anti-TB drug-induced hepatitis. Materials & methods: We compared genotype distributions of tagging SNPs in promoter, exons and haplotypes in seven drug-metabolizing enzyme genes (CYP2C9, CYP2C19, CYP2D6, CYP2E1, NAT2, UGT1A1 and UGT1A3) between 67 cases and 159 controls. Results: Among four tagging SNPs of N-acetyltransferase 2 (NAT2), -9796T>A in promoter and R197Q were significantly associated (p = 0.0016 and p = 0.0007, respectively). NAT2 haplotype 2 [A-A-A-G] carrying A allele of -9796T>A and A allele of R197Q showed significant association (p = 0.0004). However, there was no significant association between genotypes of other enzyme-metabolizing genes and anti-TB drug-induced hepatitis. The constructs containing -9796A of NAT2 showed significantly lower luciferase activity (p < 0.01), suggesting decreased expression of NAT2. The variant alleles and haplotype 2 showed significantly higher peak serum levels of isoniazid, lower acetyl isoniazid:isoniazid ratio and lower isoniazid clearance compared with wild-types. Conclusion: These findings suggest that genetic variants in the promoter and exons of NAT2 increase the risk of anti-TB drug-induced hepatitis by modifying acetylation phenotypes and/or gene expression of NAT2, and there is no essential role for genetic mutation of the other metabolizing enzymes in the development of this adverse reaction.
- Keywords
- anti-TB drug; drug-metabolizing enzyme; hepatitis; N-acetyltransferase 2; polymorphism; ISONIAZID-INDUCED HEPATOTOXICITY; 1ST-LINE ANTITUBERCULOSIS DRUGS; S-TRANSFERASE M1; RISK-FACTORS; N-ACETYLTRANSFERASE-2 GENE; HAPLOTYPE ANALYSIS; TUBERCULOSIS; ASSOCIATION; POPULATION; GENOTYPE
- URI
- https://oasis.postech.ac.kr/handle/2014.oak/26196
- DOI
- 10.2217/PGS.09.100
- ISSN
- 1462-2416
- Article Type
- Article
- Citation
- PHARMACOGENOMICS, vol. 10, no. 11, page. 1767 - 1779, 2009-11
- Files in This Item:
- There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.